EMBRYONIC STEM CELLS IN SAFETY PHARMACOLOGY AND TOXICOLOGY

被引:0
作者
Stummann, Tina C. [1 ]
Bremer, Susanne [1 ]
机构
[1] ECVAM, Ispra, Italy
来源
NEW TECHNOLOGIES FOR TOXICITY TESTING | 2012年 / 745卷
关键词
VITRO EMBRYOTOXICITY TESTS; IN-VITRO; HAZARD ASSESSMENT; RISK ASSESSMENT; DRUG DISCOVERY; MOUSE EMBRYOS; TOXICITY; DIFFERENTIATION; RECOMMENDATIONS; CARDIOMYOCYTES;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Embryonic stem (ES) cells undergo self-renewal and are pluripotent, i.e., they can give rise to all the types of specialised cells in the body. Scientific knowledge on ES cells is increasing rapidly, leading to opportunities for establishment of ES cell-based in vitro tests for drug discovery, preclinical safety pharmacology and toxicology. The main properties of ES cells making them useful in in vitro assays are that they have a normal diploid karyotype and can provide a large number of cells for high-throughput assays. Human ES cells additionally have the potential to provide solutions to problems related to interspecies differences and methods for screening for human polymorphisms, thus supporting robust human hazard identification and optimised drug discovery strategies. Importantly, ES cell based assays could be potential tools to reduce and perhaps replace, animal experiments. This chapter will describe ongoing research in the use of ES cells in toxicology and safety pharmacology, focusing on the major areas of progress, namely, embryotoxicology, cardiotoxicology and hepatoxicology.
引用
收藏
页码:14 / 25
页数:12
相关论文
共 61 条
[1]  
Adler S, HESC TECHNOLOG UNPUB
[2]  
[Anonymous], 1998, OECD PRINC GOOD LAB
[3]   Insulin production by human embryonic stem cells [J].
Assady, S ;
Maor, G ;
Amit, M ;
Itskovitz-Eldor, J ;
Skorecki, KL ;
Tzukerman, M .
DIABETES, 2001, 50 (08) :1691-1697
[4]  
BALLS M, 1995, ATLA-ALTERN LAB ANIM, V23, P129
[5]   The use of embryonic stem cells for regulatory developmental toxicity testing in vitro -: The current status of test development [J].
Bremer, S ;
Hartung, T .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (22) :2733-2747
[6]   Detection of the embryotoxic potential of cyclophosphamide by using a combined system of metabolic competent cells and embryonic stem cells [J].
Bremer, S ;
Pellizzer, C ;
Coecke, S ;
Paparella, M ;
Catalani, P .
ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 2002, 30 (01) :77-85
[7]   Establishment of an in vitro reporter gene assay for developmental cardiac toxicity [J].
Bremer, S ;
Worth, AP ;
Paparella, M ;
Bigot, K ;
Kolossov, E ;
Fleischmann, BK ;
Hescheler, J ;
Balls, M .
TOXICOLOGY IN VITRO, 2001, 15 (03) :215-223
[8]   Myocardial regeneration strategies using human embryonic stem cell-derived cardiomyocytes [J].
Capi, Oren ;
Gepstein, Lior .
JOURNAL OF CONTROLLED RELEASE, 2006, 116 (02) :211-218
[9]   Can human embryonic stem cells contribute to the discovery of safer and more effective drugs? [J].
Cezar, Gabriela Gebrin .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2007, 11 (04) :405-409
[10]   Guidance on Good Cell Culture Practice - A report of the second ECVAM task force on Good Cell Culture Practice [J].
Coecke, S ;
Balls, M ;
Bowe, G ;
Davis, J ;
Gstraunthaler, G ;
Hartung, T ;
Hay, R ;
Merten, OW ;
Price, A ;
Schechtman, L ;
Stacey, G ;
Stokes, W .
ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 2005, 33 (03) :261-287